Legato Capital Management’s Krystal Biotech KRYS Stock Holding History

Legato Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.24M	Buy	8,713 +1,740	+25%	+$520K	0.27%	114
2026 Q1	$1.8M	Buy	6,973 +5,060	+265%	+$1.35M	0.16%	184
2025 Q4	$472K	Sell	1,913 -1,844	-49%	-$388K	0.04%	566
2025 Q3	$663K	Buy	+3,757	New	+$562K	0.07%	401
2025 Q2	–	Sell	-5,190	Closed	-$936K	–	588
2025 Q1	$936K	Buy	+5,190	New	+$873K	0.13%	273
2024 Q4	–	Sell	-1,791	Closed	-$326K	–	597
2024 Q3	$326K	Sell	1,791 -431	-19%	-$83.1K	0.04%	501
2024 Q2	$408K	Buy	+2,222	New	+$373K	0.06%	466
2024 Q1	–	Sell	-5,099	Closed	-$633K	–	594
2023 Q4	$633K	Sell	5,099 -5,841	-53%	-$648K	0.08%	362
2023 Q3	$1.27M	Sell	10,940 -1,795	-14%	-$219K	0.18%	185
2023 Q2	$1.5M	Buy	12,735 +1,795	+16%	+$183K	0.2%	159
2023 Q1	$876K	Hold	10,940	–	–	0.16%	223
2022 Q4	$867K	Buy	+10,940	New	+$812K	0.17%	206
2021 Q3	–	Sell	-5,882	Closed	-$400K	–	265
2021 Q2	$400K	Buy	+5,882	New	+$411K	0.06%	275

Other funds holding KRYS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Legato Capital Management's KRYS Position: Q2 2026 in Review

Legato Capital Management increased its Krystal Biotech (KRYS) stake by 25% in Q2 2026, buying an estimated $520K and bringing the position to 8,713 shares worth $3.24M. The position accounts for 0.27% of the portfolio, ranked #114.

Legato Capital Management first reported a position in KRYS in Q2 2021 and has held it in 13 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

Legato Capital Management held 8,713 shares of Krystal Biotech worth $3.24M as of Q2 2026.
Legato Capital Management bought 1,740 Krystal Biotech shares in Q2 2026, an estimated $520K.
Krystal Biotech made up 0.27% of Legato Capital Management's portfolio in Q2 2026, its #114 holding.
Legato Capital Management first reported a position in Krystal Biotech in Q2 2021 and has held it in 13 quarters since.
423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Legato Capital Management's 13F filing for Q2 2026, filed 6 Aug 2026.